These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1033031)

  • 1. Competitive dihydrofolate reductase binding assay of triazinate (NSC-139105), methasquin (NSC-122870), and aminopterin (NSC739).
    Myers CE; Eliot HM; Chabner BA
    Cancer Treat Rep; 1976 May; 60(5):615-6. PubMed ID: 1033031
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1972 Oct; 32(10):2120-6. PubMed ID: 4404161
    [No Abstract]   [Full Text] [Related]  

  • 3. Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine.
    Philips FS; Sirotnak FM; Sodergren JE; Hutchison DJ
    Cancer Res; 1973 Jan; 33(1):153-8. PubMed ID: 4682318
    [No Abstract]   [Full Text] [Related]  

  • 4. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.
    Sirotnak FM; Donsback RC
    Cancer Res; 1975 Jul; 35(7):1737-44. PubMed ID: 1169115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
    Chello PL; McQueen CA; DeAngelis LM; Bertino JR
    Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of codon 22 mutations on substrate and inhibitor binding for human dihydrofolate reductase.
    Ercikan E; Waltham M; Dicker A; Schweitzer B; Bertino JR
    Adv Exp Med Biol; 1993; 338():515-9. PubMed ID: 8304170
    [No Abstract]   [Full Text] [Related]  

  • 7. Number of binding sites and possible mechanisms of action.
    Condit PT
    Ann N Y Acad Sci; 1971 Nov; 186():363-4. PubMed ID: 4943807
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.
    Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM
    Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818
    [No Abstract]   [Full Text] [Related]  

  • 9. Similar characteristics of folate analogue transport in vitro in contrast to varying dihydrofolate reductase levels in epithelial cells at different stages of maturation in mouse small intestine.
    Sirotnak FM; Moccio DM; Yang CH
    Cancer Res; 1984 Nov; 44(11):5204-11. PubMed ID: 6488181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculation of relative binding free energy difference of DHFR inhibitors by a finite difference thermodynamic integration (FDTI) approach.
    Kamath S; Coutinho E; Desai P
    J Biomol Struct Dyn; 1999 Jun; 16(6):1239-44. PubMed ID: 10447207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate. I. Pharmacology and pharmacokinetics.
    Lippens RJ
    Am J Pediatr Hematol Oncol; 1984; 6(4):379-95. PubMed ID: 6398629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biochemical aspects of folate transport].
    Totskiĭ VN; Bondarchuk NG
    Usp Sovrem Biol; 1979; 88(3):353-66. PubMed ID: 395787
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of the cellular oxidation-reduction state in methotrexate binding to dihydrofolate reductase and dissociation induced by reduced folates.
    Matherly LH; Anderson LA; Goldman ID
    Cancer Res; 1984 Jun; 44(6):2325-30. PubMed ID: 6609765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas.
    Li WW; Lin JT; Tong WP; Trippett TM; Brennan MF; Bertino JR
    Cancer Res; 1992 Mar; 52(6):1434-8. PubMed ID: 1371715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence and properties of dihydrofolate reductases within the genus Trypanosoma.
    Gutteridge WE; Jaffe JJ; McCormack JJ
    Br J Pharmacol; 1968 Sep; 34(1):191P-192P. PubMed ID: 4300138
    [No Abstract]   [Full Text] [Related]  

  • 16. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH; Barlowe CK; Goldman ID
    Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of dihydrofolate reductase inhibted by methotrexate or aminopterin.
    Jackson RC; Niethammer D; Hart LI
    Arch Biochem Biophys; 1977 Aug; 182(2):646-56. PubMed ID: 561567
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro.
    Matherly LH; Voss MK; Anderson LA; Fry DW; Goldman ID
    Cancer Res; 1985 Mar; 45(3):1073-8. PubMed ID: 2578870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties.
    Ercikan-Abali EA; Waltham MC; Dicker AP; Schweitzer BI; Gritsman H; Banerjee D; Bertino JR
    Mol Pharmacol; 1996 Mar; 49(3):430-7. PubMed ID: 8643082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells.
    Cohen M; Bender RA; Donehower R; Myers CE; Chabner BA
    Cancer Res; 1978 Sep; 38(9):2866-70. PubMed ID: 679194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.